Phase Ib/II Study Of CRLX 101 (Cerulean) In Combination With Bevacizumab In The Treatment Of Patients With Advanced Renal Cell Carcinoma

Trial Profile

Phase Ib/II Study Of CRLX 101 (Cerulean) In Combination With Bevacizumab In The Treatment Of Patients With Advanced Renal Cell Carcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Camptothecin (Primary) ; Bevacizumab
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Jun 2016 According to a Cerulean Pharma media release, primary endpoint of recommended phase II dose (A primary aim in phase Ib is to determine the recommended phase II camptothecin dose has been met.
    • 04 Nov 2015 According to a Cerulean Pharma media release, results from this study were presented at the 2015 International Kidney Cancer Symposium.
    • 02 Jun 2015 Final results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top